Investor Presentation FY26 Q1 June 2025 Disclaimer CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain information contained in this presentation constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this presentation that are not statements of historical fact may be deemed to be forward-looking statements. Forward looking statements are often identified by terms such as "may", "should", "anticipate", "expect", "potential", "believe", "intend ...

Financial Performance - Total revenue increased by 09% to $1350 million[3] - Adjusted EBITDA decreased by 24% to $326 million[3] - Adjusted EBITDA margin decreased by 90 bps to 241%[3] - AFFO increased 551% to $211 million[3] - AFFO per share increased 80% to $081[3] - GAAP net loss of $(7) million, or $(003) per diluted common share[3] Guidance - Full-year 2025 adjusted EBITDA is now expected to be $129 to $134 billion, revised down from the prior guidance of $135 to $140 billion[5] - Adjusted FFO per share for full-year 2025 is expected to be $320 to $340, revised down from the prior guidance of $340 to $360[5] - Third-quarter 2025 adjusted EBITDA is expected to be $326 to $336 million[5] - Third-quarter 2025 AFFO per share is expected to be $075 to $079[5]

Adynatrace Q1 2026 Investor Presentation August 6, 2025 Legal Disclaimer This presentation consists of theses slides and the associated remarks and comments, which are related and intended to be presented and understood together. Pease refer of certain terms. Cautionary Language Concerning Forward-Looking Statements This presentation inducles sertain "forward-lobing statements" within the maning of the Printer Securities Litication Reform At of 1299, induling statements regarding Dyn and current be withs th ...

Investor Presentation: Half-year 2025 Safe harbour statements NOTE REGARDING FORWARD-LOOKING STATEMENTS: CERTAIN STATEMENTS AND INDICATIVE PROJECTIONS (WHICH MAY INCLUDE MODELLED LOSS SCENARIOS) MADE IN THIS PRESENTATION OR OTHERWISE THAT ARE NOT BASED ON CURRENT OR HISTORICAL FACTS ARE FORWARD-LOOKING IN NATURE INCLUDING, WITHOUT LIMITATION, STATEMENTS CONTAINING THE WORDS "BELIEVES", "AIMS", "ANTICIPATES", "PLANS", "PROJECTS", "FORECASTS", "GUIDANCE", "INTENDS", "EXPECTS", "ESTIMATES", "PREDICTS", "MAY", ...

Financial Performance - Net earnings per diluted share decreased by 642% from $310 in 2Q24 to $111 in 2Q25[9] - Adjusted earnings per diluted share decreased by 27% from $183 in 2Q24 to $178 in 2Q25[9] - Adjusted earnings per diluted share excluding foreign currency impact decreased by 55% from $183 in 2Q24 to $173 in 2Q25[9] - U S GAAP ROE decreased from 283% in 2Q24 to 90% in 2Q25[12] - Adjusted ROE decreased from 143% in 2Q24 to 137% in 2Q25[12] - Adjusted ROE excluding foreign currency remeasurement decreased from 175% in 2Q24 to 164% in 2Q25[12] Business Segment Performance - Aflac Japan's premium persistency remained relatively stable at 933% in 2Q24 and 937% in 2Q25[15] - Aflac Japan's QTD actual operating ratios for 2Q25 include a benefit ratio of 665%, an expense ratio of 206%, and a pretax profit margin of 320%[18] - Aflac U S's persistency remained relatively stable at 787% in 2Q24 and 792% in 2Q25[20] - Aflac U S's QTD actual operating ratios for 2Q25 include a benefit ratio of 473%, an expense ratio of 363%, and a pretax profit margin of 225%[22] Capital Management - The company's estimated regulatory ESR in Japan is >240% and the combined RBC ratio in the U S is >600% as of June 30, 2025[24] - The company's adjusted leverage ratio increased from 195% in 2Q24 to 225% in 2Q25[29]

Financial Performance - Lantheus' Q2 2025 revenues were $378 million, a decrease of 4.1% compared to Q2 2024[15, 52] - Adjusted EPS for Q2 2025 was $1.57, a decrease of 12.8% year-over-year[15, 52] - Radiopharmaceutical Oncology sales were $250.6 million, down 8.3% year-over-year, but with a 4% sequential volume increase[52] - Precision Diagnostics sales were $115.8 million, up 3.3% year-over-year, driven by DEFINITY sales growth of 7.5%[52] - Strategic Partnerships sales were $11.6 million, up 32.8% year-over-year[52] Financial Position - Cash provided by operations increased to $87.1 million in Q2 2025 from $84.7 million in Q2 2024[55] - Free cash flow for Q2 2025 was $79.1 million[58] - Lantheus has $695.6 million in cash on hand and $750 million available in revolving credit[58] Guidance - Updated FY 2025 revenue guidance is $1.475 billion - $1.51 billion[61] - Updated FY 2025 adjusted fully diluted EPS guidance is $5.50 - $5.70[61] Strategic Initiatives - Lantheus anticipates four key product launches in the next 18 months: MK-6240, OCTEVY, PNT2003, and a new PSMA PET formulation[20] - The company has a board authorization for a new $400 million stock repurchase program[59]

2Q 2025 Financial Highlights - Adjusted net revenue reached $2.4 billion, reflecting a growth of 2%, or 5% on a constant currency basis excluding dispositions[11] - Adjusted operating margin was 44.6%, an increase of 130 basis points, or 110 basis points excluding dispositions[11] - Adjusted EPS stood at $3.10, representing an 11% increase, or 11% on a constant currency basis[11] - The company generated strong adjusted free cash flow with a 108% conversion rate[10] Segment Performance - Merchant Solutions reported adjusted net revenue of $1.8 billion, up 1%, or 5.5% on a constant currency basis excluding dispositions, with an adjusted operating margin of 50.1%, up 130 basis points[13] - Issuer Solutions reported adjusted net revenue of $547 million, up 4%, or 3.5% on a constant currency basis, with an adjusted operating margin of 48.7%, up 190 basis points[13] Key Metrics - New partners increased by 15% for merchants and 28% for issuers[15] - Traditional accounts on file growth was 9%[15] - Bookings growth was 13%[15] 2025 Outlook - The company anticipates adjusted net revenue growth of 5% to 6% on a constant currency basis excluding dispositions[17] - Adjusted operating margin expansion is expected to be greater than 50 basis points excluding dispositions[17] - Adjusted EPS growth is projected to be at the high end of 10% to 11% on a constant currency basis[17] - Adjusted free cash flow conversion is expected to be 90%+[17] Strategic Initiatives - The company is entering into a $500 million accelerated share repurchase plan in connection with the Payroll divestiture[10] - Capital return expectations for 2025-2027 have been raised to $7.5 billion, excluding returns associated with asset dispositions[10] - The expected annual run-rate operating income benefit from operational transformation has been increased to $650 million[10]

Financial Performance - Uber's Q2 2025 revenue reached $12651 million, representing an 18% increase year-over-year[54] - Adjusted EBITDA for Q2 2025 was $2119 million, a 35% increase year-over-year[57] - Mobility gross bookings grew to $23762 million in Q2 2025, an 18% increase in constant currency year-over-year[63] - Delivery gross bookings increased to $21734 million in Q2 2025, reflecting a 20% growth in constant currency year-over-year[70] - Freight revenue remained relatively stable at $1261 million in Q2 2025, showing a (1%) change in constant currency year-over-year[75] Operational Metrics - Monthly Active Platform Consumers (MAPCs) increased by 15% year-over-year, reaching 180 million in Q2 2025[42] - Total trips grew by 18% year-over-year to 3268 million in Q2 2025[44] - Monthly trips per MAPC (Frequency) increased by 2% year-over-year to 61 in Q2 2025[43] Strategic Initiatives - Uber One membership program has 36 million members and accounts for over 40% of combined Delivery & Mobility bookings[31, 32] - Uber is expanding its AV technology commercialization, with deployments in 12 cities across 3 countries and plans for ~5 additional cities in 2025[35, 36]

Q3 2025 Performance - Underlying sales growth was 3%[13], impacted by reduced pricing actions due to improved tariff exposure[13] - Adjusted EPS of $1.52 met the top end of guidance[13] - Free cash flow generation exceeded expectations, yielding a 21.3% margin[11] Orders and Demand - Underlying orders grew by 4%[13]; Test & Measurement orders increased by 16%[13] - Strong demand continues in process and hybrid markets, with discrete markets showing recovery[10] - Industrial software saw strong demand, with Annual Contract Value (ACV) at $1.5 billion, up 10% year-over-year[10] Q4 2025 Guidance - Expects underlying sales growth between 5% and 6%[11], driven by Test & Measurement recovery and automation investments[11] - Anticipates an adjusted segment EBITA margin of approximately 27%[11], higher than previously expected due to lower tariff exposure[11] - Projects adjusted EPS of $1.58 to $1.62, representing a 7% to 10% year-over-year increase[11] Tariff Mitigation - Reduced tariff exposure by approximately $210 million annualized[21], expecting full offset[21] - Gross tariffs are estimated at $455 million annualized[22], with mitigations of approximately $130 million[22] through price and supply chain actions[22] Full Year 2025 Guidance - Free Cash Flow raised to approximately $3.2 billion[32], with an ~18% margin[32] - Price is now expected to contribute ~2.5 percentage points due to the improved tariff environment[32]

Financial Performance - Revenue reached €10.3 billion, a 2.5% increase[29] - Operating profit increased by 7.2% to €1.4 billion[12, 29] - Comparable free cash flow was €0.4 billion[12, 29] - Interim dividend per share is €0.79[12, 29] Strategic Initiatives and Growth - The company is targeting €350-400 million in efficiencies by 2028 through a productivity mindset[7, 32] - The company reaffirms FY25 profit and cash guidance[10] - The company expects revenue growth of 3% to 4% for FY25[33] - The company expects operating profit growth of approximately 7% for FY25[33] Market and Portfolio - Non-Alcoholic Ready-To-Drink (NARTD) represents a €170 billion market in 2024[9] - Hot Coffee represents a €9 billion market in 2024[9] - Hot Tea represents a €5 billion market in 2024[9] Shareholder Value - The company has returned approximately €7.8 billion in cash since 2016[7] - The company is executing a new share buyback program of approximately €460 million[13, 29, 33]